Consensus Eli Lilly and Company

Stocks

LLY

US5324571083

Pharmaceuticals

Market Closed - NYSE 16:00:02 2026-10-23 EDT			5-day change	1st Jan Change
1,273.46 ^USD	-2.54%		+1.31%	+18.50%

11:45am	Roche Targets Emerging Oncology Market With New Lung-Cancer Drug	DJ
10-24	Eli Lilly And Company Presents First Clinical Data In Platinum-Sensitive Ovarian Cancer For Its Investigational, Next-Generation, FRa-Targeting ADC At ESMO 2026	CI

Evolution of the Average Target: Eli Lilly and Company

Evolution of the Target Price: Eli Lilly and Company

Changes in Analyst Recommendations: Eli Lilly and Company

d195820f6ddd0237.j-JtQZBxCz_D5uneS9j0nF2v1CB5SmyacPKFC3dQhmk._88oM-ErRkevsITvZpW3-QXL5VkWKR_YQt-9bBsR7VH1uhku3BBzXYmKoA~42cd8c60da6b547da5baca7e121befc4

Analysts' recommendations: Eli Lilly and Company

10-22	5 Healthcare Stocks to Watch as Investors Look Beyond Big Tech
10-20	Goldman Sachs Adjusts Price Target on Eli Lilly to $1,413 From $1,371	MT
10-19	Eli Lilly's Foundayo to Keep Gaining Market Share Over Next 12 Months, BofA Says	MT
10-19	BofA Securities Adjusts Eli Lilly Price Target to $1,397 From $1,341, Maintains Buy Rating	MT
10-12	Eli Lilly Likely to Post Strong Volume Growth in Q3, RBC Says	MT
10-12	Eli Lilly Likely to Raise Revenue Outlook Amid Strong Diabetes, Weight-Loss Drug Sales, RBC Says	MT
10-12	RBC Forecasts Eli Lilly Q3 Sales Beat, FY26 Guidance Upgrade Amid 'Strong' Volume Growth	MT
10-09	BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating	MT
10-08	Cantor Fitzgerald Adjusts Price Target on Chime Financial to $1,440 From $1,410	MT
10-07	Morgan Stanley Adjusts Price Target on Eli Lilly to $1,430 From $1,419	MT
10-02	Top Midday Decliners	MT
10-01	Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says	MT
10-01	BMO Expects Eli Lilly's 'Increasingly Differentiated' Obesity Portfolio to Support Patient Retention	MT
09-28	JPMorgan Adjusts Price Target on Eli Lilly to $1,500 From $1,400, Maintains Overweight Rating	MT
09-18	Guggenheim Adjusts Price Target on Eli Lilly and Co. to $1,284 From $1,273, Keeps Buy Rating	MT
09-17	Goldman Sachs Adjusts Eli Lilly Price Target to $1,371 From $1,367, Maintains Buy Rating	MT
09-15	Berenberg Upgrades Eli Lilly to Buy
09-15	Analyst recommendations: Abercrombie & Fitch, Eli Lilly, Philip Morris, Ulta Beauty…
09-15	Berenberg Upgrades Eli Lilly and Co. to Buy From Hold, Adjusts Price Target to $1,400 From $1,220	MT
09-15	Eli Lilly Rating, Price Target Up as Berenberg Notes 'Underestimated' External Pipeline Moves	MT
09-10	HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating	MT
09-03	Rothschild & Co Redburn Adjusts PT on Eli Lilly and Co. to $930 From $915, Keeps Neutral Rating	MT
08-27	Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth Concerns	DJ
08-17	Top Midday Gainers	MT
08-14	China Merchants Adjusts Eli Lilly Price Target to $1,252 From $964, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+4.56%
	JOHNSON & JOHNSON					+5.91%
	ABBVIE INC.					-0.3%
	ROCHE HOLDING AG					-1.29%
	MERCK & CO., INC.					+9.97%
	NOVARTIS AG					-1.87%
	ASTRAZENECA PLC					+22.49%
	AMGEN INC.					-9.69%
	GILEAD SCIENCES, INC.					+2.66%
	NOVO NORDISK A/S					+14.58%
	Average					+4.70%
	Weighted average by Cap.					+4.32%